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Abstract
Background & aims: Duchenne muscular dystrophy results from a mutation in the dystrophin gene, which leads to a 
dystrophin-deficiency. Dystrophic muscle is marked by progressive muscle injury and loss of muscle fibers. 
Activation of the PGC-1a pathway has been previously shown to decrease disease- related muscle damage. Oral 
administration of the flavonol, quercetin, appears to be an effective and safe method to activate the PGC-1a pathway. 
The aim of this investigation was to determine the extent to which long term dietary quercetin enrichment would 
decrease muscle injury in dystrophic skeletal muscle. We hypothesized that a quercetin enriched diet would rescue 
dystrophic muscle from further decline and increase utrophin abundance.
Methods: Beginning at three-months of age and continuing to nine-months of age mdx mice (n ¼ 10/ group) were 
assigned to either to mdx-control receiving standard chow or to mdx-quercetin receiving a 0.2% quercetin-enriched 
diet. At nine-months of age mice were sacrificed and costal diaphragms collected. One hemidiaphragm was used for 
histological analysis and the second hemidiaphragm was used to determine gene expression via RT-qPCR.
Results: The diaphragm from the mdx-quercetin group had 24% (p ::: 0.05) more muscle fibers/area and 34% (p ::: 
0.05) fewer centrally nucleated fibers compared to the mdx-control group. Further, there were 44% (p ::: 0.05) fewer 
infiltrating immune cells/area, a corresponding 31% (p ::: 0.05) reduction in TNF gene expression, and a near 50% 
reduction in fibrosis. The quercetin-enriched diet increased expression of genes associated with oxidative metabolism 
but did not increase utrophin protein abundance.
Conclusions: Long-term quercetin supplementation decreased disease-related muscle injury in dystrophic skeletal 
muscle; however the role of PGC-1a pathway activation as a mediator of this response is unclear.
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s ummary 
Background & aims: Duchenne muscular dystrophy results from a mutation in the dystrophin gene, 
which leads to a dystrophin-deficiency. Dystrophic muscle is marked by progressive muscle injury and 
loss of muscle fibers. Activation of the PGC-1a pathway has been previously shown to decrease disease- 
related muscle damage. Oral administration of the flavonol, quercetin, appears to be an effective and safe 
method to activate the PGC-1a pathway. The aim of this investigation was to determine the extent to 
which long term dietary quercetin enrichment would decrease muscle injury in dystrophic skeletal 
muscle. We hypothesized that a quercetin enriched diet would rescue dystrophic muscle from further 
decline and increase utrophin abundance. 
Methods: Beginning at three-months of age and continuing to nine-months of age mdx mice (n ¼ 10/ 
group) were assigned to either to mdx-control receiving standard chow or to mdx-quercetin receiving a 
0.2% quercetin-enriched diet. At nine-months of age mice were sacrificed and costal diaphragms 
collected. One hemidiaphragm was used for histological analysis and the second hemidiaphragm was 
used to determine gene expression via RT-qPCR. 
Results: The diaphragm from the mdx-quercetin group had 24% (p ::: 0.05) more muscle fibers/area and 
34% (p ::: 0.05) fewer centrally nucleated fibers compared to the mdx-control group. Further, there were 
44% (p ::: 0.05) fewer infiltrating immune cells/area, a corresponding 31% (p ::: 0.05) reduction in TNF gene 
expression, and a near 50% reduction in fibrosis. The quercetin-enriched diet increased expression of genes 
associated with oxidative metabolism but did not increase utrophin protein abundance. 
Conclusions: Long-term quercetin supplementation decreased disease-related muscle injury in dystrophic 
skeletal muscle; however the role of PGC-1a pathway activation as a mediator of this response is unclear. 
. 
1. Introduction
Duchenne muscular dystrophy (DMD) is caused by dystrophin 
protein deficiency. Dystrophin serves as a link between the actin 
cytoskeleton and the extracellular matrix through the dystrophin- 
glycoprotein complex (DGC) [1]. DMD is marked by loss of muscle 
function resulting in wheelchair confinement and death due to 
respiratory or cardiac failure generally in the third decade of life [2]. 
Non-standard abbreviations: PGC-1a, peroxisome proliferator-activated receptor 
gamma coactivator 1-alpha (Ppargc1a); DMD, Duchenne muscular dystrophy; DGC, 
dystrophin-glycoprotien  complex. 
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This disease is modeled by the mdx mouse. The diaphragm of the 
mdx mouse most accurately recapitulates disease progression [3]. 
Transgenic   over-expression   and   neonatal   gene   delivery   of 
peroxisome  proliferator-activated  receptor  gamma  coactivator  1- 
alpha  (Ppargc1a;  PGC-1a)  prevented  or  delayed  disease  onset
[4,5] and gene delivery also rescued actively declining skeletal 
muscle [6]. Nutraceutical-mediated activation of the PGC-1a 
pathway could make this approach translatable to DMD patients. 
Resveratrol, a polyphenol, is thought to be a PGC-1a activator via 
Sirtuin-1 (Sirt1) [7] or AMPK [8]. Because of the equivocal results 
[4,7,9,10] and significant safety concerns [4] with resveratrol we 
sought out a compound that could drive the PGC-1a pathway, be 
rapidly administered to the DMD population, and had an excellent 
safety profile. Quercetin, a flavonol, met all of these requirements. 
 
 
 
Table 1 
Primer sequences used for qPCR. 
 
Primer name Primer sequence Accession number Length of amplicon 
Tnf mouse For ccccaaagggatgagaagtt NM_013693.3 132 
Tnf mouse Rev cacttggtggtttgctacga   
Myog mouse For tccagtacattgagcgccta NM_031189.2 238 
Myog mouse Rev acgatggacgtaagggagtg   
Myod1 mouse For agtgaatgaggccttcgaga NM_010866.2 222 
Myod1 mouse Rev gcatctgagtcgccactgta   
Mef2c mouse For cactagcactcatttatctc NM_001170537.1 178 
Mef2c mouse Rev acagctgctcaagctgtcaa   
Myf5 mouse For tgagggaacaggtggagaac NM_008656.5 198 
Myf5 mouse Rev agctggacacggagctttta   
Myh3 mouse For acgacaactcgtctcgcttt NM_001099635.1 205 
Myh3 mouse Rev ttggtcgtaatcagcagcag   
Myh7/MhcI mouse For agatgaatgccgagctcact NM_080728.2 170 
Myh7/MhcI mouse Rev ctcatccaaaccagccatct   
Myh2/MhcIIa mouse For gagcaaagatgcagggaaag NM_001039545.2 228 
Myh2/MhcIIa mouse Rev taagggttgacggtgacaca   
Myh4/MhcIIb mouse For ggggctgtaccagaaatccg NM_010855.3 142 
Myh4/MhcIIb mouse Rev cctgaagagagctgacacgg   
Myh1/MhcIIx mouse For agaagctcctgggatccatt NM_030679.1 168 
Myh1/MhcIIx mouse Rev ctctcgccaagtaccctctg   
Nrf2 mouse For ggggaacagaacaggaaaca NM_008065.2 208 
Nrf2 mouse Rev ccgtaatgcacggctaagtt   
Utrn 30  mouse For cgacaacatctggggaagat NM_011682.4 173 
Utrn 30  mouse Rev gtgctctggccacatactga   
Utrn 50  mouse For gtttgaggtgcttcctcagc NM_011682.4 203 
Utrn 50  mouse Rev gcgatatctggtagctgtcc   
Esrra/Erra mouse For 
Esrra/Erra  mouse  Rev 
ccaggcttctcctcactgtc 
gccccctcttcatctaggac 
NM_007953.2 152 
Cycs mouse For ccaaatctccacggtctgtt NM_007808.4 192 
Cycs mouse Rev gtctgccctttctcccttct   
Nrf1 mouse For gcacctttggagaatgtggt NM_001164226.1 165 
Nrf1 mouse Rev ctgagcctgggtcattttgt   
Tfam mouse For ccaaaaagacctcgttcagc NM_009360.4 211 
Tfam mouse Rev cttcagccatctgctcttcc   
Tfb1m mouse For ctcctggacttgaggctgac NM_146074.1 170 
Tfb1m mouse Rev aaccctgggataaagcgagt   
Tfb2m mouse For tagagccgttgcctgattct NM_008249.4 194 
Tfb2m mouse Rev taatgccccagtcaggattc   
Mteco2/CoxII mouse For acgaaatcaacaaccccgta AF378830.1 172 
Mteco2/CoxII mouse Rev ggcagaacgactcggttatc   
Uqcrc1 mouse For gacaacgtgaccctccaagt NM_025407.2 249 
Uqcrc1 mouse Rev actggtacataggcgcatcc   
18S RT-primer gagctggaattaccgcggct NR_003278.3  
18S mouse For gggaggtagtgacgaaaaataacaat NR_003278.3 101 
18S mouse Rev ttgccctccaatggatcct   
 
Quercetin is a potent Sirt1 activator [11] capable of entering 
muscle cells following oral delivery [12,13], which can lead to PGC- 
1a deacetylation and subsequent activation [14]. Importantly, oral 
administration of quercetin to mice [14] increased mRNA abun- 
dance of Sirt1 and PGC-1a and induced mitochondrial biogenesis in 
skeletal muscle. Quercetin may be beneficial to dystrophic skeletal 
muscle because of cellular pathway activation and/or through in- 
dependent secondary effects including antioxidant and anti- 
inflammatory functions [15,16]. Also, quercetin is safe at high- 
doses (up to 12,000 mg/kg/day) for up to two years [17e21]. 
Therefore, the purpose of this investigation was to determine the 
extent to which long-term dietary quercetin enrichment would 
decrease injury in dystrophic skeletal muscle. We hypothesized 
that quercetin would rescue declining dystrophic skeletal muscle 
and increase utrophin abundance without causing obvious 
toxicities. 
 
2. Methods 
 
2.1. Animal treatments 
 
All animal procedures were approved by the IACUC at Iowa State 
University and were done in accordance with the guiding principles 
established by the American Physiological Society. At three-months 
of age 20 mdx mice were randomly divided in two groups receiving 
either standard chow (BioServe, Rodent diet) or standard diet 
enriched with 0.2% quercetin (BioServe, Rodent diet þ 0.2% quer- 
cetin) for six months. During the study period mice were weighed 
weekly and food consumption was recorded biweekly. At nine- 
months of age mice were anesthetized to a surgical plane with 
tribromoethanol, sacrificed by cervical dislocation, and the costal 
diaphragm removed and divided into hemidiaphragms. One hem- 
idiaphragm was snap frozen in liquid nitrogen for measures of gene 
expression and the other was coated in freezing media and frozen 
for histological analyses. 
 
2.2. Histology 
 
Ten-micron frozen sections were cut from the diaphragm and 
placed on slides. Hematoxylin and Eosin staining was performed 
according to standard techniques. Each diaphragm section was 
visualized using a Leica microscope at 100x and 2e4 images were 
taken of each diaphragm. Following a cursory inspection of slides 
from each group we hypothesized that diaphragms from quercetin 
treated animals had a greater abundance of muscle fibers compared 
to control fed mice. Using Image J [22] the total number of skeletal 
 
 
muscle fibers and the number of skeletal muscle fibers with a 
centralized nucleus were counted in two images/section (77e330 
fibers/image). Data are reported as the average (±SEM) of these two 
images. 
To identify utrophin protein localization and abundance, utro- 
phin antibody ((1:10 dilution, Vector VP-U579) directly labeled 
with Zeon Alexa 568 (Invitrogen Z25006) was used as previously 
described [6]. To evaluate fibronectin abundance, an indicator of 
fibrosis, sections were first blocked with 5% BSA. Sections were 
incubated with anti-fibronectin antibody ((1:100, Sigma F3648) at 
4 oC overnight. The next day slides were washed three times with 
PBS. Following the wash, sections were incubated with fluorescein 
conjugated goat anti-mouse IgG at (1:100; Millipore) for 1 h in the 
dark. After the incubation period slides were washed three times in 
PBS and then cover slips were applied and sealed. To visualize 
measures. All other data from control and quercetin-treated mdx 
mice were compared using a Student's t-test. For gene expression 
statistics were performed on the dCT. Gene expression data are 
presented as fold change as calculated from ddCT. Significance was 
set at p ::: 0.05. All data are expressed as means ± SEM unless 
otherwise  noted. 
 
3. Results 
 
Three-month old mdx mice were fed a control or 0.2% 
quercetin-enriched diet for six months. Food consumption fluctu- 
ated similarly throughout the study period in both groups with an 
average food consumption of 3.8 ± 0.03 g/day of control food and an 
average food consumption of 3.6 ± 0.02 g/day of quercetin enriched 
food (Fig. 1(A)). Body mass of the mice in both groups increased as 
fibronectin abundance for each Section 1e3 non-overlapping 200x 
images were taken under identical exposure conditions. To quantify they aged (p ::: 0.05) but did not differ between groups (Fig. 1(B)). 
protein abundance IHC images were converted into binary images 
using OpenLab (version 3.5.1, Perkin Elmer) as previously described 
[6]. 
Determination of fiber type differences by IHC was done in two 
serial sections. Sections were washed and blocked as described for 
fibronection. One section was incubated with primary antibody for 
MhcI (A4.951, Hybridoma Bank University of Iowa developed by 
Blau, H.M.) and laminin (NeoMarkers, RB-082-A) the second sec- 
tion was incubated with primary antibody for MhcIIa (SC-71, Hy- 
bridoma Bank University of Iowa developed by Schiaffino, S.) and 
laminin. Primary myosin antibodies were detected using fluores- 
cein conjugated goat anti-mouse IgG at 1:100 (Millipore, 12e506) 
and laminin was detected with goat anti-rabbit rhodamine conju- 
gated IgG (Millipore, 12e510), respectively. Slides were imaged at 
200x at the same area in both serial sections. For analyses, both the 
total number of cells/image and the number of positive staining 
cells/image were counted using Image J [22]. Cells that were 
negative for MhcI and MhcIIA were considered MhcII x/b and cells 
that were positive for both myosin antibodies were considered 
MhcI/IIa fibers. The cell counts from 2 to 3 images/section were 
pooled, resulting in approximately 100e400 cells/section. 
 
2.3. Biochemistry 
 
RNA was extracted from the remaining hemidiaphragm using 
Trizol according to manufacturer recommendations (Invitrogen, 
15596-018). To eliminate organic carryover and DNA contamination 
RNA was purified using a Qiagen RNesay spin column (Qiagen 
RNeasy Mini Kit, 74106) in combination with an on-column DNase 
(Qiagen RNase free DNase set, 79254) treatment. RNA concentra- 
tion was measured using a Nanodrop (Thermo Scientific). From 1 mg 
RNA, cDNA was synthesized following manufacturer's instructions 
(QuantiTect Reverse Transcription Kit, Qiagen 205311) with the 
addition of 18S RT primers. To measure expression of genes of in- 
terest QuantiFast SYBR Green PCR kit (Qiagen, 204056), primers 
(Table 1), and 10 ng of cDNA template, were loaded into each well 
for a total 12.5 mL reaction volume. Gene expression was assayed 
with a Mastercycler EP Realplex (Eppendorf). All samples were 
measured in triplicate wells and normalized to 18S expression. 
Delta CT (dCT) values were calculated by subtracting the 18S CT 
value from the CT value for the gene of interest. ddCT was calcu- 
lated by subtraction of the highest dCT of a given gene from all the 
dCT for that gene. 
 
2.4. Statistics 
 
For body weight and food consumption control and quercetin 
treated animals were compared with an ANOVA with repeated 
Upon sacrifice at nine-months of age, mice on the control diet 
weighed 31.4 ± 1.3 g and mice on the quercetin-enriched diet 
weighed 29.5 ± 1.0 g. Gastrocnemius mass was similar between 
groups when considered as absolute mass (mdx-Con e 172 ± 9 mg; 
mdx-Q e 157 ± 8 mg) or normalized to body weight (mdx-Con e 
5.5 ± 0.1 mg/g; mdx-Q e 5.3 ± 0.1 mg/g). In addition to normal 
growth, food consumption, and muscle mass, mice treated with the 
quercetin-enriched diet did not exhibit obvious signs of toxicity 
including failure to groom or lethargy. Importantly, and in contrast 
to previous experience with resveratrol, supplementation with 
quercetin did not result in unexpected deaths. 
To determine the extent to which the quercetin-enriched diet 
protected dystrophic skeletal muscle we performed a histological 
 
 
 
Fig. 1. Body weight and food consumption during the six month study period in mdx 
mice. Data are means ± SEM. Food consumption did not differ between the control and 
quercetin diet treatment groups (A). The increase in body mass during the six month 
study period did not differ between the control and quercetin diet (B) treatment 
groups. 
 
 
 
 
Fig. 2. Representative H&E stained diaphragm sections (200x). Dystrophin-deficient mice were fed a control diet (A) or a diet containing 0.2% quercetin (B) for 6 months starting at 
3-mo of age. Following 6 months of quercetin treatment muscle fibers per area were preserved (C), central nucleation decreased (D), number of infiltrating immune cells was 
reduced per area (E) and per muscle fiber (F) compared to control fed mice. In support of decreased immune cell infiltration TNF-a transcript abundance was also decreased (G). 
Data are means ± SEM. * indicates significantly different from control-fed animals (p ::: 0.05). 
 
evaluation of the diaphragms. Following H&E staining, the dia- 
phragm sections from the quercetin-treated mdx mice exhibited 
less disease-related injury and appeared healthier than the dia- 
phragm sections from the control-treated mice (Fig. 2(A and B)). To 
objectively quantify histological changes we measured the number 
of muscle fibers, percent of fibers with centralized nuclei, and 
fibrotic area. Diaphragms from quercetin-treated mice had 24% 
(p ::: 0.05) more muscle fibers/area than diaphragms from control- 
treated mice (Fig. 2(C)). Further, there was a 34% (p ::: 0.05) decrease 
in fibers with centralized nuclei (Fig. 2(D)). Because the quercetin- 
enriched diet led to a decrease in central nucleation, we measured 
transcript abundance of genes involved in muscle regeneration. 
Relative abundance of MyoG, MyoD, Mef2c, Myf5 and embryonic 
myosin  heavy  chain  were  similar  between  groups  (Table  2). 
Corresponding with a preservation of muscle fiber number was a 
44% (p ::: 0.05) reduction in immune cell infiltration when 
normalized to section area or a 62% (p ::: 0.05) reduction when 
normalized to muscle fiber number (Fig. 2(E and F)). The reduction 
in immune cell infiltration was supported by a 31% (p ::: 0.05) 
reduction in Tnf transcript abundance in the diaphragms from the 
quercetin-enriched diet group compared to those in the control 
diet group (Fig. 2(G)). Fibrotic area was decreased by 47% (p ::: 0.05) 
in diaphragms taken from the quercetin-enriched diet group 
compared to mice in the control diet group (Fig. 3(AeC)). 
To better understand the mechanism underlying quercetin- 
mediated interruption of the disease process we assessed 
changes indicative of increased oxidative metabolism as well as 
changes associated with the slow/neuromuscular junction gene 
 
 
Table 2 
Genes that are similar between control and quercetin enriched diet. 
Fold change relative to mdx 
Gene abbreviation Fold change p-Value 
 
 
Repair 
Myog 0.97 0.74 
Myod 1.02 0.95 
Mef2 1.31 0.22 
Myf5 1.16 0.21 
Mhc3 1.03 0.79 
Fiber type 
Mhc I 0.96 0.90 
MhcIIa 1.01 0.95 
MhcIIx 0.96 0.95 
MhcIIb 0.75 0.79 
Nrf2 1.11 0.25 
Utrn 50 0.94 0.84 
Utrn 30 0.93 0.69 
 
 
 
program. Both of these are likely contributors to PGC-1a-mediated 
rescue of dystrophic muscle. Transcript abundance of mitochon- 
drial transcription factors Tfam, Tfb1m and Tfb2m were measured in 
the diaphragms of both treatment groups. Tfam transcript abun- 
dance increased 46% (p ::: 0.05) and Tfb1m abundance increased 
numerically by 28%, however, failed to reach significance (p ¼ 0.08) 
(Fig. 4) and Tfb2m did not differ between quercetin-treated and 
control groups. Abundance of the mitochondrial encoded transcript 
CoxII (Mteco2) was increased 55% (p ::: 0.05), cytochrome C (Cycs) 
exhibited a non-significant 45% numerical increase (p ¼ 0.07) with 
quercetin treatment, and UqcrcI, a component of the electron 
transport chain, was similar between groups. PGC-1a signals 
through Erra  and Nrf1 resulting in mitochondrial biogenesis, 
however, transcript abundance of Erra and Nrf1 were similar be- 
tween groups (Fig. 4). 
With activation of the PGC-1a pathway a fast-to-slow myosin 
heavy chain shift is expected. In the current study frequency of type 
I (slow), IIa, and IIb/x (fast) skeletal muscle fiber types did not differ 
between groups (mdx-control: I-20.9 ± 4.5%, I/IIa-2.2 ± 0.6%, IIa- 
 
 
 
Fig. 4. Oxidative gene expression. The relative difference between mdx-quercetin and 
mdx-control mRNA abundance was measured. Data are means ± SEM. * indicates 
significantly different from control-fed animals (p ::: 0.05) z indicates (p ::: 0.1). 
74 ± 5.0%, and IIb/x-2.7 ± 0.9%; mdx-quercetin: I-16.4 ± 3.2%,I/IIa- 
3.3 ± 0.9%, IIa-75.9 ± 3.5%, and IIb/x-4.4 ± 1.3%). Further, transcript 
abundance of MhcI (Myh7), MhcIIa (Myh2), MhcIIx (Myh1), and 
MhcIIb (Myh4) did not differ between groups (Table 2). Transcript 
abundance of Nrf2, a transcriptional activator of the slow gene 
program, did not differ between groups (Table 2). Associated with 
the slow/neuromuscular gene program is increased utrophin 
abundance. We and others have previously measured increased 
utrophin gene and protein abundance following PGC-1a pathway 
activation [4,6]. In this investigation we found that utrophin tran- 
script (Table 2) and protein (Fig. 5(AeC)) abundance were similar 
between groups. 
 
4. Discussion 
 
While the cause of DMD is well known, effective therapies to 
treat   this   disease   have   been   slow   in   reaching   the   patient 
 
 
 
Fig. 3. Representative diaphragm images of fibronection IHC. mdx-control (A) and mdx-quercetin (B) mice were either fed a control diet or a quercetin-enriched diet, respectively. 
Fibrosis was significantly reduced in mdx-quercetin diaphragms compared to mdx-control (C). Data are means ± SEM. * indicates significantly different from control-diet animals 
(p ::: 0.05). 
 
 
 
 
Fig. 5. Representative images for utrophin IHC. 100x images of diaphragms from mdx-control (A) and mdx-quercetin (B) treated mice. Utrophin abundance did not differ between 
mdx-control and mdx-quercetin treatments (C). Data are means ± SEM. 
 
 
population. We have previously shown that up regulation of PGC- 
1a protein expression via viral gene transfer prevents disease onset 
and rescues dystrophic skeletal muscle from typical disease pro- 
gression [4,6]. In order to translate this experimental approach to 
an immediately available therapy we sought nutraceuticals that 
increase PGC-1a pathway activation and have a demonstrated 
safety profile. In the current long-term feeding study we demon- 
strate that oral delivery of quercetin decreased indices of disease 
severity in diaphragms from mdx mice without obvious signs of 
toxicity. 
The current study demonstrates mdx mice fed a 0.2% quercetin- 
enriched diet had reduced muscle histopathology including pres- 
ervation of muscle fiber number and decreased fibrosis. Further, we 
also demonstrate that remaining fibers from mdx-quercetin di- 
aphragms were in generally better health than those from mdx- 
control as central nucleation was decreased following consump- 
tion of the quercetin-enriched diet. Consistent with these obser- 
vations, consumption of the  quercetin-enriched diet was  also 
associated with decreased inflammation. It was beyond the scope 
of this investigation to determine the extent to which quercetin 
treatment decreased fibrosis and inflammation directly or indi- 
rectly by interfering with other aspects of disease progression and 
skeletal muscle injury. 
Guided by our previous findings in studies using gene transfer of 
PGC-1a we tested several hypotheses to better understand the 
mechanisms leading to quercetin-mediated interruption of the 
disease process. Consistent with previous work, we found that 
quercetin treatment led to increased expression of oxidative genes. 
This outcome is important as metabolic dysregulation [23,24] and 
depleted ATP [24] content are characteristic of dystrophic muscle. 
We did not detect evidence suggesting enhanced muscle regener- 
ation, which we found in a previous study where PGC-1a gene 
transfer was used to rescue dystrophic muscle from disease pro- 
gression [6]. Contrary to our hypothesis, we did not increase rela- 
tive utrophin transcript or protein abundance. Utrophin has been 
shown to substitute for the missing dystrophin protein in dystro- 
phic skeletal muscle and restore resistance to contraction-induced 
 
injury [25,26]. Additionally, utrophin has been repeatedly increased 
by PGC-1a gene transfer studies, however, supplementation with 
resveratrol, another dietary flavonoid, has, like quercetin, also 
failed to increase utrophin protein abundance [4,9]. A recent report 
supports our hypothesis that PGC-1a pathway activation functions 
through multiple therapeutic avenues and is not solely utrophin- 
dependent [27]. Importantly, it seems likely that PGC-1a can lead 
to increased mitochondrial biogenesis independent of inducing 
gene expression associated with the neuromuscular junction and 
slow skeletal muscle as the former is driven through an Nrf1 
dependent pathway [28] while the latter is driven through an Nrf2 
dependent pathway [5]. Muscle and body mass were also similar 
between groups, which is counter to expectations given that 
virally-mediated PGC-1a overexpression led to reduced muscle 
mass. These findings and inconsistencies with viral gene transfer of 
PGC-1a suggest that, while dietary quercetin consumption did 
successfully decrease skeletal muscle injury, quercetin led to only 
partial PGC-1a pathway activation. 
Careful scrutiny of several previous reports of oral quercetin 
administration indicates dose, method, and frequency of delivery 
may be key to more robustly activating the PGC-1a pathway. In the 
current investigation quercetin was delivered in the food likely 
resulting in a consistent, though relatively small, increase in quer- 
cetin concentration for the duration of the project. This dose was 
based on previous work demonstrating a 0.2% quercetin diet 
increased plasma quercetin concentration [29]. In contrast, studies 
using the gavage technique to deliver quercetin [14,30] found 
increased PGC-1a pathway activation after one and six weeks, 
respectively, of a similar daily quercetin dose, likely causing a 
transient spike in bioavailable quercetin. In order to robustly acti- 
vate the PGC-1a pathway in skeletal muscle pulsatile spikes in 
plasma quercetin concentration may be needed rather than a 
prolonged low-level plasma quercetin concentration. Another 
consideration is that the current investigation was carried out for 
six months where the former were considerably shorter in duration 
(days to weeks). How the prolonged dosing regimen may affect 
efficacy    is    unclear,    however,    this    remains    an    important 
 
 
consideration as DMD patients would likely be treated with quer- 
cetin for an extended period. Another possibility as to why the 
present results do not more closely match those of PGC-1a gene 
transfer studies is that PGC-1a protein content is decreased in 
dystrophic skeletal muscle compared with healthy skeletal muscle 
[31], thereby limiting the capacity for activation through deacety- 
lation via Sirt1. This biological limitation is overcome in gene 
transfer studies; however magnitude of change may also be 
important as it is unlikely that supplementation studies will in- 
crease PGC-1a content to that achieved in transgenic or gene 
transfer studies. 
While data presented in this investigation suggest at least par- 
tial activation of the PGC-1a pathway an important consideration is 
that quercetin may be acting through PGC-1a-independent mech- 
anisms. Dystrophin deficiency leads to a host of maladaptations 
including oxidative stress and inflammation. Targeting of these 
contributors to  muscle  pathology  has  been previously shown to 
decrease disease severity [32e34]. Importantly, quercetin functions 
as an antioxidant and/or anti-inflammatory in a variety of cell types 
[15,35e37] and skeletal muscle taken from obese ob/ob mice [16]. 
Further, quercetin has recently been tested as an ameliorative anti- 
inflammatory and antioxidant therapy for sarcoidosis patients, an 
inflammatory disease with components of oxidative stress much 
like DMD. In this investigation quercetin decreased lipid peroxi- 
dation and inflammatory signaling [38]. 
In conclusion, we demonstrate that dietary quercetin enrich- 
ment decreased disease indices in dystrophic skeletal muscle and 
appears to be a promising therapeutic avenue. The mechanism 
responsible for the observed improvements remains to be eluci- 
dated. Increased expression of oxidative genes points toward acti- 
vation of the PGC-1a pathway, however, a failure to increase 
utrophin transcript or protein abundance indicates this pathway 
was only partially activated. We postulate that PGC-1a pathway 
activation can be maximized following careful study of dosing 
schemes. Importantly, and consistent with the established safety 
profile of quercetin, animals receiving the quercetin-enriched diet 
did not exhibit signs consistent with toxicity. 
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